Target Name: CDC42EP5
NCBI ID: G148170
Review Report on CDC42EP5 Target / Biomarker Content of Review Report on CDC42EP5 Target / Biomarker
CDC42EP5
Other Name(s): Binder of Rho GTPases 3 | 1700027J19Rik | CDC42 effector protein (Rho GTPase binding) 5 | Borg3 | CDC42 effector protein 5 | binder of Rho GTPases 3 | CEP5 | Cdc42 effector protein 5 | BORG3_HUMAN | 2010007O02Rik

CD42EP5: A Potential Drug Target and Biomarker for Rho GTPases 3

Rho GTPases are a family of small GTPases that play crucial roles in various cellular processes, including cytoskeletal organization, cell signaling, and cell-cell interactions. Rho GTPases 3 (RhoG3) is a critical protein for cell signaling and cytoskeletal organization, and it is involved in the regulation of cell adhesion, migration, and invasion. The Binder of Rho GTPases 3 (CD42EP5) is a protein that can interact with RhoG3 and regulate its activity. This interaction between CD42EP5 and RhoG3 makes it an attractive drug target and a potential biomarker for the treatment of various diseases.

CD42EP5: Structure and Function

CD42EP5 is a 21-kDa protein that is expressed in various tissues, including brain, heart, skeletal muscles, and platelets. It is a member of the P1 subfamily of the CD42 family, which includes several proteins that can interact with RhoGTPases. The CD42EP5 protein has a unique structure that consists of a long N-terminus, a transmembrane region, and a C-terminus.

The N-terminus of CD42EP5 contains a unique farnesylated cysteine residue that can interact with RhoG3. The cysteine residue is important for the stability and activity of the protein. The transmembrane region of CD42EP5 contains a unique hydrophobic domain that is important for the protein's stability and localization to the cytoskeleton. The C-terminus of CD42EP5 contains a GTP-binding site that is important for the regulation of RhoG3 activity.

CD42EP5 has been shown to interact with RhoG3 and regulate its activity. Studies have shown that CD42EP5 can inhibit the activity of RhoG3 and increase its stability. This interaction between CD42EP5 and RhoG3 can modulate the activity of RhoG3 and affect various cellular processes, including cell adhesion, migration, and invasion.

Drug Targeting and Biomarker Potential

CD42EP5 has the potential to be a drug target for various diseases due to its interaction with RhoG3. The inhibition of RhoG3 activity by CD42EP5 can be used to treat various diseases that are characterized by the over-activity of RhoG3, such as cancer, neurodegenerative diseases, and developmental disorders.

One of the potential drug targets for CD42EP5 is the treatment of cancer. Cancer is characterized by the over-activity of RhoG3, which can promote the growth and survival of cancer cells. The inhibition of RhoG3 activity by CD42EP5 can be used to treat various types of cancer, including breast, ovarian, and prostate cancer.

Another potential drug target for CD42EP5 is the treatment of neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. The over-activity of RhoG3 in these diseases can contribute to the progression of the disease. The inhibition of RhoG3 activity by CD42EP5 can be used to treat neurodegenerative diseases and potentially slow the progression of the disease.

In addition to cancer and neurodegenerative diseases, CD42EP5 may also have potential as a biomarker for the diagnosis and monitoring of various diseases. The inhibition of RhoG3 activity by CD42EP5 can be used as a therapeutic target for diseases that

Protein Name: CDC42 Effector Protein 5

Functions: Probably involved in the organization of the actin cytoskeleton. May act downstream of CDC42 to induce actin filament assembly leading to cell shape changes. Induces pseudopodia formation in fibroblasts. Inhibits MAPK8 independently of CDC42 binding. Controls septin organization and this effect is negatively regulated by CDC42 (By similarity)

The "CDC42EP5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC42EP5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C